Kanpur Dehat’s 2-year-old girl gets Covaxin jab, first in Uttar Pradesh

New Delhi: In what may be one of the youngest vaccination beneficiary yet in Uttar Pradesh, a 2 year and 8-month-old girl was administered the COVID-19 jab.  During the ongoing trial of Covaxin on young children, the toddler was given the first dose of the indigenous COVID vaccine. The girl who was administered the vaccine … Read more

COVID-19 vaccines prevent deaths, finds study

A single dose of COVID-19 vaccine was 82% effective in preventing deaths while two doses were 95% effective, an analysis of data on Tamil Nadu police personnel has indicated. Data on vaccination of police personnel and COVID-19 deaths during the second wave was used to estimate the incidence of deaths among vaccinated and unvaccinated police … Read more

India likely to have COVID vaccine for children above 2 years by September-October: AIIMS Director

Noting that children usually have a mild disease but there is a need to develop COVID-19 vaccines for them, AIIMS Delhi Director Dr Randeep Guleria has said Bharat Biotech and other companies are doing trials at a very fast pace and hoped that data will lead to approvals so that there is a vaccine for … Read more

Day Before Bharat Biotech's Meet with WHO, Covaxin's Phase 3 Trial Data to be Reviewed by Expert Panel

File photo of Bharat Biotech’s Covaxin. The phase 3 trial data will clearly state the efficacy of the Covid-19 vaccine. Bharat Biotech, the developers of Covaxin, had already been in the dock for delay in announcing its trial data. The Subject Expert Committee (SEC), a group of independent experts that advises the national drug regulator, … Read more

Bharat Biotech has submitted Covaxin’s Phase III trial data to DCGI: Govt sources

The Hyderabad-based Covid vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin to Drugs Controller General of India (DCGI) over the weekend, according to government sources. “We have received the data from the phase III trials,” a senior government official confirmed. Bharat Biotech’s Covaxin is one of the three … Read more

Coronavirus updates | Covaxin moves a step closer to WHO nod

The average daily COVID-19 vaccination rate in the first 10 days of June was relatively higher than the levels recorded initially in May after India opened up inoculation for all adults. From June 1 to 10, 3 mn average daily doses were administered. At the current rate, by July 31, around 403 mn doses can … Read more

Covaxin does not contain newborn calf serum: Centre busts myths | India News – Times of India

NEW DELHI: The indigenously developed Covaxin does not contain newborn calf serum, clarified Centre on Wednesday. The statement came in response to some social media posts which the government said have “twisted and misrepresented” facts on the Covid-19 vaccine developed by Bharat Biotech. Newborn calf serum is used only for the preparation and growth of … Read more

Rs 150 per Covaxin dose to Centre not sustainable in long run: Bharat Biotech

The supply price of Bharat Biotech‘s COVID-19 vaccine Covaxin to the Central government at Rs 150 per dose is not sustainable in the long run, the vaccine maker said on Tuesday. Hence a higher price in private markets is required to offset part of the costs, it said in a statement. The Centre’s supplying price … Read more

Amid Clamour for Phase 3 Trials Data, Bharat Biotech Says 'Committed to Transparency'

Bharat Biotech on Saturday said scientific standards and commitment of the indigenously-developed Covid-19 vaccine Covaxin are transparent, and the company has so far published nine research studies on its safety and efficacy. “Covaxin’s scientific standards+commitment is transparent. Academic journals, peer reviewers, NIV-ICMR-BB researchers -scientists,9 studys & data published,” BharatBiotech CoFounder & Joint MD Suchitra Ella … Read more

Bharat Biotech shares elaborate data of all research studies of Covaxin

India’s first indigenous COVID-19 vaccine manufacturer- Bharat Biotech on Saturday shared comprehensive data of all research studies of Covaxin. As per the company release, the complete data for Phase I and II, and partial data for Phase III trials of Covaxin have been thoroughly scrutinised by the regulators in India. Covaxin, a whole-virion inactivated coronavirus … Read more